ERBB2 and breast carcinoma: Another example that does not use anti-checkpoint antibodies but combines the anti-HER2 mAb trastuzumab with a cell-based vaccine, consisting of two irradiated allogeneic mammary carcinoma cell lines genetically modified to secrete human GM-CSF, has been used for the treatment of HER2+ metastatic breast tumors (NCT00399529).